☆ 4.8 Article

A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

JOURNAL OF CLINICAL INVESTIGATION (2021)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Robert L. Gottlieb et al.

Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial

Elena Diago-Sempere et al.

Summary: The ConPlas-19 study aims to evaluate the efficacy and safety of convalescent plasma for adult patients with severe COVID-19 pneumonia through a multicenter, randomized, controlled trial. 278 hospitalized patients will be randomly assigned to receive convalescent plasma plus standard care or standard care alone, and followed for 30 days to assess progression of the disease. Interim analyses will be conducted at different enrollment milestones to evaluate efficacy and futility.

TRIALS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Piyada Supasa et al.

Summary: Research on the UK-dominant variant B.1.1.7 shows that it is harder to neutralize than the parental virus, but widespread escape from antibodies or monoclonal antibodies has not been observed yet.

CELL (2021)

Add to Collection

Article Medicine, General & Internal

Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial

Maria Elvira Balcells et al.

Summary: The study did not find evidence of benefit in mortality, length of hospitalization, or mechanical ventilation requirement by immediate addition of CP therapy in the early stages of COVID-19 compared to its use only in case of patient deterioration.

PLOS MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Peter W. Horby et al.

Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

Arvind Gharbharan et al.

Summary: A clinical trial on 86 COVID-19 patients treated with convalescent plasma showed no overall clinical benefit, as most patients already had potent antibodies upon admission, leading to the trial being terminated prematurely.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Michael A. Thompson et al.

Summary: This study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19. Results showed that convalescent plasma treatment was associated with improved 30-day mortality, especially in patients requiring intensive care unit admission or mechanical ventilatory support.

JAMA ONCOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

Max R. O'Donnell et al.

Summary: This study found that the use of convalescent plasma was not associated with significant improvement in the clinical status at day 28 for severe COVID-19 patients, but it was related to significantly improved survival rates.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Editorial Material Medicine, Research & Experimental

The convalescent sera option for containing COVID-19

Arturo Casadevall et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Pooling Data From Individual Clinical Trials in the COVID-19 Era

Eva Petkova et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial

Ling Li et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Multidisciplinary Sciences

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19

Kening Li et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Review Immunology

The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis

John Mair-Jenkins et al.

JOURNAL OF INFECTIOUS DISEASES (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.